Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy after retroperitoneal lymph node dissection.

K W Brunner, R W Sonntag

    Progress in Clinical and Biological Research
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation.

    Annals of oncology : official journal of the European Society for Medical Oncology·2003
    Same author

    Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer.

    The Journal of urology·2001
    Same author

    Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage i nonseminomatous germ cell tumor.

    The Journal of urology·2000
    Same author

    Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.

    The Journal of urology·1999
    Same author

    ["primum nil nocere" and clinical cancer research. Observations on a controversy].

    Schweizerische medizinische Wochenschrift·1994
    Same author

    Present and future projects of the International Breast Cancer Study Group.

    Cancer·1994
    Same journal

    DNA homology and chromosome stability: a sensitive yeast genetic system for identifying double-stranded DNA damage.

    Progress in clinical and biological research·2018
    Same journal

    Endotoxin and sepsis: molecular mechanisms of pathogenesis, host resistance, and therapy. Proceedings of the 4th Conference of the International Endotoxin Society. Nagoya, Japan, October 23-27, 1996.

    Progress in clinical and biological research·1998
    Same journal

    The pathogenic role of LBP in gram-negative sepsis and septic shock.

    Progress in clinical and biological research·1998
    Same journal

    The role of interleukin 6 in endotoxin-induced inflammatory responses.

    Progress in clinical and biological research·1998
    Same journal

    Role of nitric oxide and reactive oxygen species in endotoxin shock.

    Progress in clinical and biological research·1998
    Same journal

    Interaction of lipopolysaccharide with a mammalian lyso-phosphatidate acyltransferase (LPAAT) transfected into E. coli, and effect of lisofylline on LPAAT transfected into mammalian cells.

    Progress in clinical and biological research·1998
    See all related articles

    Adjuvant chemotherapy for stage II testicular cancer post-RPLND lacks firm data. Risk stratification is key to personalize treatment, balancing chemotherapy toxicity against cure rates for relapse.

    Area of Science:

    • Oncology
    • Urologic Oncology
    • Clinical Trials

    Background:

    • Adjuvant chemotherapy use in stage II testicular cancer after retroperitoneal lymph node dissection (RPLND) lacks definitive data.
    • Balancing potential benefits of adjuvant chemotherapy against high cure rates with salvage chemotherapy for recurrent disease is crucial.

    Purpose of the Study:

    • To evaluate the role and optimal strategy of adjuvant chemotherapy in stage II testicular cancer following RPLND.
    • To identify patient subgroups that may benefit from adjuvant chemotherapy versus salvage therapy or immediate chemotherapy.

    Main Methods:

    • Analysis of relapse rates after RPLND in stage I and II testicular cancer patients.
    • Assessment of salvage chemotherapy efficacy based on risk factors (tumor burden, histology, disease site).

    Related Experiment Videos

    Main Results:

    • Relapse rates are 10-15% for stage I and 40-50% for stage II testicular cancer post-RPLND.
    • Salvage chemotherapy achieves complete remission in 50-70% of relapsed patients, with success varying by risk factors.
    • Low-risk patients may not need adjuvant chemotherapy due to high salvage cure rates; high-risk patients may benefit significantly.

    Conclusions:

    • Adjuvant chemotherapy is not routinely indicated for all stage II testicular cancer patients post-RPLND.
    • Risk stratification can identify patients who benefit from adjuvant chemotherapy, those suitable for surveillance, and those needing immediate intensive treatment.
    • Randomized clinical trials are necessary to define optimal treatment strategies for different patient subgroups.